Current Rheumatology Reports

, Volume 9, Issue 4, pp 336–341 | Cite as

Kawasaki disease: 40 years after the original report



The cause of Kawasaki disease (KD) remains unknown, although a number of epidemiologic and clinical observations suggest it is triggered by one or more infectious agents, each of which can result in the clinical manifestation of the disease. Advances have been made in the management of the disease with the introduction of aspirin and intravenous immunoglobulin (IVIG), which have had a significant impact on lowering the rate of coronary artery aneurysms and death from the disease. Questions remain regarding the management of those patients who fail to respond to IVIG. It appears that some patients with severe KD who are resistant to IVIG may benefit from IV pulse steroid therapy or infliximab infusion. However, a recent multicenter, randomized, controlled trial did not support the addition of a pulsed dose of intravenous methylprednisolone to the conventional IVIG therapy for the primary treatment of KD. It remains to be seen whether other anti-inflammatory agents such as immunosuppressive therapies or new biologics will play a role in the management of patients with KD.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Taubert KA, Rowley AH, Shulman ST: Nationwide survey of Kawasaki disease and acute rheumatic fever. J Pediatr 1991, 119:279–282.PubMedCrossRefGoogle Scholar
  2. 2.
    Kawasaki T: Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes [in Japanese]. Arerugi 1967, 16:178–222.PubMedGoogle Scholar
  3. 3.
    Yanagawa H, Nakamura Y, Ojima T, et al.: Changes in epidemic patterns of Kawasaki disease in Japan. Pediatr Infect Dis J 1999, 18:64–66.PubMedCrossRefGoogle Scholar
  4. 4.
    Holman RC, Belay ED, Clarke MJ, et al.: Kawasaki syndrome among American Indian and Alaska native children. Pediatr Infect Dis J 1999, 18:451–455.PubMedCrossRefGoogle Scholar
  5. 5.
    Holman RC, Curns AT, Belay ED, et al.: Kawasaki syndrome hospitalizations in the United States. Pediatrics 2003, 112:495–501.PubMedCrossRefGoogle Scholar
  6. 6.
    Mason WH, Takahashi M: Kawasaki syndrome. Clin Infect Dis 1999, 28:169–185.PubMedGoogle Scholar
  7. 7.
    Yanagawa H, Yashiro M, Nakamura Y, et al.: Nationwide surveillance of Kawasaki disease in Japan. Pediatr Infect Dis J 1995, 14:69–71.PubMedGoogle Scholar
  8. 8.
    Cohen BJ: Human parvovirus B19 infection in Kawasaki disease [letter]. Lancet 1994, 344:59.PubMedCrossRefGoogle Scholar
  9. 9.
    Marchette NJ, Melish ME, Hicks R, et al.: Epstein-Barr virus and other herpes infections in Kawasaki syndrome. J Infect Dis 1990, 161:680–684.PubMedGoogle Scholar
  10. 10.
    Dominguez SR, Anderson MS, Glodé MP, et al.: Blinded case-control study of the relationship between human coronavirus NL63 and Kawasaki disease. J Infect Dis 2006, 194:1697–1701.PubMedCrossRefGoogle Scholar
  11. 11.
    Dajani AS, Taubert KA, Gerber MA, et al.: Diagnosis and therapy of Kawasaki disease in children. Circulation 1993, 87:1776–1780.PubMedGoogle Scholar
  12. 12.
    Abinum M, Cant AJ: Toxic shock syndrome toxin-secreting staphylococcus aureus in Kawasaki syndrome [letter]. Lancet 1994, 343:300.CrossRefGoogle Scholar
  13. 13.
    Davis HD, Kirk V, Jadavji T, et al.: Simultaneous presentation of Kawasaki disease and toxic syndrome in an adolescent male. Pediatr Infect Dis J 1996, 15:1136–1137.CrossRefGoogle Scholar
  14. 14.
    Meissner HC, Leung DY: Superantigens, conventional antigens and etiology of Kawasaki syndrome. Pediatric Infect Dis J 2000, 19:91–94.CrossRefGoogle Scholar
  15. 15.
    Leung DY, Meissner HC, Fulton DR, et al.: Toxic shock syndrome toxin-secreting staphylococcus aureus in Kawasaki syndrome. Lancet 1993, 342:1385–1387.PubMedCrossRefGoogle Scholar
  16. 16.
    Terai M, Miwa K, Williams T, et al.: The absence of evidence of staphylococcal toxin involvement in the pathogenesis of Kawasaki disease. J Infect Dis 1995, 172:558–561.PubMedGoogle Scholar
  17. 17.
    Rowley AH, Shulman ST: New developments in the search for etiologic agent of Kawasaki disease. Curr Opin Pediatr 2007, 19:71–74.PubMedCrossRefGoogle Scholar
  18. 18.
    Dajani AS, Taubert KA, Gerber MA, et al.: Diagnosis and therapy of Kawasaki disease in children. Circulation 1993, 87:1776–1780.PubMedGoogle Scholar
  19. 19.
    Takahashi K, Oharaseki T, Naoe S, et al.: Neutrophilic involvement in the damage to coronary arteries in acute stage of Kawasaki disease. Pediatr Int 2005, 47:305–310.PubMedCrossRefGoogle Scholar
  20. 20.
    Rowley AH, Shulman ST, Spike BT, et al.: Oligoclonal IgA response in the vascular wall in acute Kawasaki disease. J Immunol 2001, 166:1334–1343.PubMedGoogle Scholar
  21. 21.
    Brown TJ, Crawford SE, Cornwall ML, et al.: CD8 T lymphocytes and macrophages infiltrate coronary arteryaneurysm in acute Kawasaki disease. J Infect Dis 2001, 184:940–943.PubMedCrossRefGoogle Scholar
  22. 22.
    Gavin PJ, Crawford SE, Shulman ST, et al.: Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease. Arterioscler Thromb Vasc Biol 2003, 23:576–581.PubMedCrossRefGoogle Scholar
  23. 23.
    Senzaki H: The pathophysiology of coronary artery aneurysms in Kawasaki disease: role of matrix metalloproteinases. Arch Dis Child 2006, 91:847–851.PubMedCrossRefGoogle Scholar
  24. 24.
    Suzuki A, Miyagawa-Tomota S, Komatsu K, et al.: Immunohistochemical study of apparently intact coronary artery in a child after Kawasaki disease. Pediatr Int 2004, 46:590–596.PubMedCrossRefGoogle Scholar
  25. 25.
    Kawasaki T, Kosaki T, Okawa S, et al.: A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974, 54:271–276.PubMedGoogle Scholar
  26. 26.
    Morens D, O’Brien R: Kawasaki disease in the United States. J Infect Dis 1978, 137:91–93.PubMedGoogle Scholar
  27. 27.
    Newburger JW, Takahashi M, Gerber MA, et al.: Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004, 114:1708–1733.PubMedCrossRefGoogle Scholar
  28. 28.
    Freeman AF, Shulman ST: Kawasaki disease: Summary of the American Heart Association Guidelines. Am Fam Physicians 2006, 74:1141–1148.Google Scholar
  29. 29.
    Beiser AS, Takahasha M, Baker AL, et al.: A predictive instrument for coronary artery aneurysms in Kawasaki disease. Am J Cardiol 1998, 81:1116–1120.PubMedCrossRefGoogle Scholar
  30. 30.
    Harada K: Indication for intravenous gammaglobulin treatment for Kawasaki disease. In Proceedings of the Fourth International Symposium on Kawasaki Disease. Edited by Takahasha M, Taubert K. Dallas, TX: American Heart Association; 1993:459–462.Google Scholar
  31. 31.
    Mori M, Imagawa T, Yasui K, et al.: Predictors of coronary artery lesions after intravenous gammaglobulin treatment in Kawasaki disease. J Pediatr 2000, 137:177–180.PubMedCrossRefGoogle Scholar
  32. 32.
    Nakamura Y, Yashiro M, Uehara R, et al.: Use of laboratory data to identify risk factors of giant coronary aneurysms due to Kawasaki disease. Pediatr Int 2004, 46:33–38.PubMedCrossRefGoogle Scholar
  33. 33.
    Fukunishi M, Kikkawa M, Hamana K, et al.: Prediction of non-responsiveness to intravenous high dose gammaglobulin therapy in patients with Kawasaki disease at onset. J Pediatr 2000, 137:172–176.PubMedCrossRefGoogle Scholar
  34. 34.
    Abuhammour WM, Hasan RA, Eljamal A, Asmar B: Kawasaki disease hospitalizations in a predominantly African-American population. Clin Pediatr 2005, 44:721–725.CrossRefGoogle Scholar
  35. 35.
    Porcalla AR, Sable CA, Patel KM, et al.: The epidemiology of Kawasaki disease in an urban hospital: does African American race protect against coronary artery aneurysms? Pediatr Cardiol 2005, 26:775–781.PubMedCrossRefGoogle Scholar
  36. 36.
    Marquez J, Gedalia O, Candia L, et al.: Kawasaki disease: Clinical spectrum of 88 patients in a high prevalence African American population. J Natl Med Assoc 2007, in press.Google Scholar
  37. 37.
    Newburger JW, Takahashi M, Beiser AS, et al.: A single intravenous in fusion of gammaglobulin as compared with four infusions in treatment of acute Kawasaki syndrome. N Engl J Med 1991, 324:1633–1639.PubMedCrossRefGoogle Scholar
  38. 38.
    Sundel RP, Burns JC, Baker A, Beiser A: Gamma globulin retreatment in Kawasaki disease. J Pediatr 1993, 123:657–659.PubMedCrossRefGoogle Scholar
  39. 39.
    Wright DA, Newburger JW, Baker A, Sundel RP: Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996, 128:146–149.PubMedCrossRefGoogle Scholar
  40. 40.
    Kato H, Koike S, Yokoyama T: Kawasaki disease: Effect of treatment on coronary artery involvement. Pediatrics 1979, 3:175–179.Google Scholar
  41. 41.
    Kijima Y, Kamiya T, Suzuki A, et al.: A trial procedure to prevent aneurysm formation of the coronary artery by steroid pulse therapy in Kawasaki disease. Jap Circ J 1982, 46:1239–1242.PubMedGoogle Scholar
  42. 42.
    Nonaka Z, Maekawa K, Okabe T, et al.: Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. In Kawasaki disease. Proceedings of the 5th International Kawasaki disease Symposium. Edited by Kato H. Amsterdam: Elsevier Science BV; 1995:328–331.Google Scholar
  43. 43.
    Shinohara M, Sone K, Tomomasa T, Morikawa A: Corticosteroids in the treatment of acute phase of Kawasaki disease. J Pediatr 1999, 135:465–469.PubMedCrossRefGoogle Scholar
  44. 44.
    Sundel RP, Baker AL, Fulton DR, Newburger JW: Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr 2003, 142:611–616.PubMedCrossRefGoogle Scholar
  45. 45.
    Inoue Y, Okada Y, Shinohara M, et al.: A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J Pediatr 2006, 149:336–341.PubMedCrossRefGoogle Scholar
  46. 46.
    Newburger JW, Sleeper LA, McCrindle BW, et al.: Randomized trial of pulsed corticosteroids therapy for primary for treatment of Kawasaki disease. N Engl J Med 2007, 356:663–675.PubMedCrossRefGoogle Scholar
  47. 47.
    Petty RE, Cassidy JT: Kawasaki disease. In Textbook of Pediatric Rheumatology, 4th edn. Edited by Cassidy JT, Petty RE. Oxford: W.B. Saunders Company; 2001:580–594.Google Scholar
  48. 48.
    Weiss JE, Eberhard BA, Chowdhury D, Gotrlieb BS: Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 2004, 31:808–810.PubMedGoogle Scholar
  49. 49.
    Burns JC, Mason WH, Hauger SB, et al.: Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005, 146:662–667.PubMedCrossRefGoogle Scholar
  50. 50.
    Kavey RE, Allada V, Daniels SR, et al.: Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2006, 114:2710–2738.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Department of Pediatrics/RheumatologyChildren’s HospitalNew OrleansUSA

Personalised recommendations